Assessment of Nectin4-expression in vulvar squamous cell carcinomas (VSCC): correlation with HPV-associated and HPV-independent molecular subtypes
Most VSCC show high expression of Nectin4, including the HPV-independent VSCC containing a TP53-mutation (p16<sup>-ve</sup>/p53<sup>abn</sup> molecular subtype), that are associated with the worst prognosis. Therefore, Nectin4-directed ADC such as Enfortumab-Vedotin (EV) may present a potential treatment option in VSCC. Nectin4-expression can easily be assessed by immunohistochemistry on diagnostic biopsies. Clinical trials exploring Nectin4-directed ADCs such as EV are necessary.
Authors
- C. Blake Gilks (ORCID: https://orcid.org/0000-0001-7889-8250)
- Grit Gesine Ruth Hiller
- Christine Brambs (ORCID: https://orcid.org/0000-0001-7682-2172)
- Lars‐Christian Horn (ORCID: https://orcid.org/0000-0002-9775-4858)
- Jessica N. McAlpine (ORCID: https://orcid.org/0000-0001-6003-485X)
- Amy Jamieson (ORCID: https://orcid.org/0000-0002-3210-9102)
- Benjamin Wolf (ORCID: https://orcid.org/0000-0002-1931-5198)
- Anne Kathrin Höhn
- Lien Hoang
- Mirjam Forberger
Institutions
- University of British Columbia (CA)
- University of Lucerne (CH)
- Vancouver General Hospital (CA)
- University Hospital Leipzig (DE)
Publication Details
- Journal
- Human Pathology
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1016/j.humpath.2025.105926
- Citations
- 2
- Primary Topic
- Urinary and Genital Oncology Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.01